Kraig Biocraft Laboratories Provides Production Update on Recombinant Spider Silk Operations
Kraig Biocraft Laboratories (OTCQB: KBLB) has announced significant progress in its recombinant spider silk production operations. The company is currently executing its largest-ever production batch, with the first half already completed and cocoons being prepared for silk reeling. The second half is expected to finish within 14 days.
The current production run represents a milestone as the first simultaneous batches of BAM-1 produced in their newest facilities. Initial results show promising performance of the BAM-1 hybrids and effectiveness of the expanded infrastructure. The company has also completed production of all BAM-1 hybrid eggs scheduled for release next month, ensuring consistent supply for upcoming production cycles.
According to CEO Kim Thompson, this successful execution of simultaneous production demonstrates their technology's scalability from batch processing to continuous flow manufacturing.
Kraig Biocraft Laboratories (OTCQB: KBLB) ha annunciato importanti progressi nelle sue operazioni di produzione di seta di ragno ricombinante. L'azienda sta attualmente eseguendo il suo lotto di produzione più grande di sempre, con la prima metà già completata e i bozzoli in preparazione per la filatura della seta. La seconda metà dovrebbe terminare entro 14 giorni.
Questo ciclo di produzione rappresenta una pietra miliare come i primi lotti simultanei di BAM-1 prodotti nelle loro strutture più recenti. I risultati iniziali mostrano prestazioni promettenti degli ibridi BAM-1 e l’efficacia dell'infrastruttura ampliata. L'azienda ha inoltre completato la produzione di tutte le uova degli ibridi BAM-1 previste per il rilascio il prossimo mese, garantendo una fornitura costante per i cicli produttivi futuri.
Secondo il CEO Kim Thompson, questa riuscita esecuzione della produzione simultanea dimostra la scalabilità della loro tecnologia, passando dal processo a lotti alla produzione a flusso continuo.
Kraig Biocraft Laboratories (OTCQB: KBLB) ha anunciado avances significativos en sus operaciones de producción de seda de araña recombinante. La compañía está ejecutando actualmente su lote de producción más grande hasta la fecha, con la primera mitad ya completada y los capullos preparados para el devanado de la seda. Se espera que la segunda mitad finalice en un plazo de 14 días.
Esta producción representa un hito al ser los primeros lotes simultáneos de BAM-1 producidos en sus instalaciones más nuevas. Los resultados iniciales muestran un desempeño prometedor de los híbridos BAM-1 y la efectividad de la infraestructura ampliada. La empresa también ha completado la producción de todos los huevos híbridos BAM-1 programados para ser liberados el próximo mes, asegurando un suministro constante para los próximos ciclos de producción.
Según el CEO Kim Thompson, esta exitosa ejecución de la producción simultánea demuestra la escalabilidad de su tecnología, pasando del procesamiento por lotes a la fabricación en flujo continuo.
Kraig Biocraft Laboratories (OTCQB: KBLB)가 재조합 거미줄 생산 작업에서 중요한 진전을 발표했습니다. 회사는 현재 최대 규모의 생산 배치를 진행 중이며, 전반부는 이미 완료되어 고치를 실 뽑기에 준비하고 있습니다. 후반부는 14일 이내에 완료될 예정입니다.
이번 생산은 최신 시설에서 동시에 생산된 BAM-1 배치로서 중요한 이정표를 의미합니다. 초기 결과는 BAM-1 하이브리드의 유망한 성능과 확장된 인프라의 효율성을 보여줍니다. 또한 회사는 다음 달 출시 예정인 모든 BAM-1 하이브리드 알 생산을 완료하여 향후 생산 주기에 안정적인 공급을 확보했습니다.
CEO 김 톰슨에 따르면, 이번 동시 생산의 성공적인 수행은 배치 처리에서 연속 흐름 제조로 기술의 확장성을 입증하는 것입니다.
Kraig Biocraft Laboratories (OTCQB : KBLB) a annoncé des progrès significatifs dans ses opérations de production de soie d’araignée recombinante. La société exécute actuellement son plus grand lot de production à ce jour, la première moitié étant déjà terminée et les cocons préparés pour le filage de la soie. La seconde moitié devrait s’achever dans les 14 jours.
Cette production représente une étape importante en tant que premiers lots simultanés de BAM-1 produits dans leurs installations les plus récentes. Les premiers résultats montrent des performances prometteuses des hybrides BAM-1 et l’efficacité de l’infrastructure élargie. La société a également achevé la production de tous les œufs hybrides BAM-1 prévus pour une sortie le mois prochain, assurant un approvisionnement constant pour les prochains cycles de production.
Selon le PDG Kim Thompson, cette exécution réussie de la production simultanée démontre la scalabilité de leur technologie, passant du traitement par lots à la fabrication en flux continu.
Kraig Biocraft Laboratories (OTCQB: KBLB) hat bedeutende Fortschritte bei der Produktion von rekombinantem Spinnenseide erzielt. Das Unternehmen führt derzeit seinen bisher größten Produktionsauftrag durch, wobei die erste Hälfte bereits abgeschlossen ist und Kokons für das Abhaspeln der Seide vorbereitet werden. Die zweite Hälfte soll innerhalb von 14 Tagen abgeschlossen sein.
Dieser Produktionslauf stellt einen Meilenstein dar, da es die ersten gleichzeitig produzierten Chargen von BAM-1 in ihren neuesten Anlagen sind. Erste Ergebnisse zeigen vielversprechende Leistungen der BAM-1-Hybride und die Effektivität der erweiterten Infrastruktur. Das Unternehmen hat außerdem die Produktion aller für den nächsten Monat geplanten BAM-1-Hybrid-Eier abgeschlossen, um eine gleichbleibende Versorgung für kommende Produktionszyklen sicherzustellen.
CEO Kim Thompson erklärt, dass diese erfolgreiche gleichzeitige Produktion die Skalierbarkeit ihrer Technologie vom Chargenprozess zur kontinuierlichen Fertigung demonstriert.
- Successfully executing largest-ever production batch of spider silk
- Demonstrated capability for simultaneous production batches
- Completed production of BAM-1 hybrid eggs for next month's operations
- Successfully scaled up from batch processing to continuous flow manufacturing
- None.
ANN ARBOR, Mich., April 21, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), a world leader in spider silk technology*, is pleased to provide an update on recombinant spider silk production. The Company continues to increase its production output and is now in the middle of its largest-ever batch of recombinant spider silk production.
Kraig Labs can now report that it has successfully completed the first half of its current production batch and those spider silk cocoons are being prepared for reeling into finished silk. This second half of this production cycle is expected to be complete in the next 14 days.
This current production run marks a significant milestone, as the first simultaneous batches of BAM-1 produced in the Company's newest facilities. The initial results have been highly encouraging, demonstrating the robustness of the BAM-1 hybrids and the efficiency of the expanded production infrastructure. The concurrent operation of multiple batches has proceeded smoothly, underscoring the scalability and reliability of the Company’s production model.
In addition to the progress in silk production, Kraig Labs has completed the production of all BAM-1 hybrid eggs designated for release over the next month. This achievement ensures a steady supply of high-quality hybrids for upcoming production cycles, aligning with the Company's strategic objectives and production goals for 2025.
"The successful execution of simultaneous production batches in our new facilities demonstrates the scalability of our technology from batch processing to continuous flow manufacturing," said Kim Thompson, Founder and CEO of Kraig Labs. "With this cycle nearing completion and the next generation of BAM-1 hybrids already prepared, we are in a strong position to rapidly accelerate the growth and commercialization of our spider silk."
Kraig Labs remains committed to advancing the commercialization of its eco-friendly and high-performance spider silk fibers. The Company will continue to provide updates as it progresses toward its production and commercialization goals.
For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.
For details about other recent Kraig Labs advancements, please watch the Company's investor conference at www.kraiglabs.com/videos or on the Company's YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270.
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news
* For a description of our historical leadership in this technology, please follow this link https://www.kraiglabs.com/world-leader/
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com
FAQ
What is the current status of KBLB's spider silk production batch?
How is KBLB's BAM-1 hybrid performing in the new facilities?
What production milestone has KBLB achieved with BAM-1 hybrid eggs?
How is KBLB transitioning from batch processing to continuous manufacturing?
